Six studies utilizing IL-17 inhibitors such as secukinumab and ixekizumab, which block IL-17 A, and brodalumab, which blocks the IL-17 receptor, in the treatment of scarring alopecia were identified (Table 2). This evidence concerns the gene IL17A and alopecia.